Back to News
Market Impact: 0.15
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Source: zacks.com
Analyst EstimatesHealthcare & Biotech
The article says CRISPR Therapeutics (CRSP) may beat expectations in its upcoming earnings report, citing a favorable combination of two key ingredients. It provides no figures or detail on those factors, so the potential beat is unquantified.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CRSP0.40
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Why is Apple stock falling afterhours today?
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Vornado earnings missed by $0.12, revenue fell short of estimates